Streetbeat News

Regulatory

MSOS

Chicago Atlantic Managing Partner Peter Sack discusses the impact of Trump's endorsement on cannabis rescheduling, indicating it's a matter of 'when' rather than 'if'. This could have implications for cannabis-related stocks and ETFs.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:09 pm

MSOS

Verano President Darren Weiss expressed optimism about the rescheduling of cannabis by 2025, noting the record speed of administrative agencies. However, he refrained from making specific timing predictions.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:08 pm

JNJ

Verb Surgical has been granted a US patent for a machine-learning-based visual-haptic system for robotic surgical platforms. This development could enhance the capabilities of robotic surgery, potentially impacting companies involved in this sector.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:05 pm

MSOS

The Benzinga Cannabis Capital Conference discusses the impact of the potential repeal of the 280E tax code on cannabis companies. The focus is on how different companies might benefit financially from this change.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:03 pm

TSNDF

TerrAscend's Executive Chairman, Jason Wild, expressed optimism about potential regulatory changes that would allow the cannabis industry to be treated like other industries. This could have significant implications for companies like TerrAscend.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:01 pm

MSOS

SPY

Emily Paxhia of Poseidon Investment Management highlights the challenges faced by cannabis businesses, including limited access to credit card processing, insurance, banking, and capital markets like NASDAQ and NYSE.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:59 pm

MSOS

TSNDF

TerrAscend's Executive Chairman, Jason Wild, highlighted a Supreme Court Justice's opinion questioning the legality of cannabis. This suggests potential interest in revisiting cannabis laws, which could impact cannabis-related stocks.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:57 pm

SAVA

Cassava Sciences Inc. (NASDAQ:SAVA) has settled SEC charges for $40 million over misleading statements related to its Alzheimer's drug trial. The settlement allows the company to focus on its drug development. HC Wainwright upgraded the stock to Buy with a $116 price target, anticipating positive trial results.

Portfolio Pulse from Vandana Singh

October 08, 2024 | 2:57 pm

MSOS

SPY

Emily Paxhia, Founding Partner of Poseidon Investment Management, highlighted that Supreme Court Justice Thomas wrote a dictum that could invite a case back to the Supreme Court. This development may have implications for cannabis-related investments.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:55 pm

SMCI

Super Micro Computer, Inc. (NASDAQ:SMCI) launched a new high-density AI infrastructure platform, causing its stock to initially rise but then fall. The company is under pressure due to a DOJ probe following a short report alleging inappropriate revenue recognition. SMCI shares are down 5.97%.

Portfolio Pulse from Erica Kollmann

October 08, 2024 | 2:55 pm